CN Bio

Visit CN Bio's website (click on the logo)

CN Bio logo

CN Bio logo

Board members

Emma Sceats

Emma Sceats

Chief Executive Officer

Maureen Coleman

Maureen Coleman

Executive Chairman

David Hughes

David Hughes

Chief Technology Officer

David Scales

David Scales

Board Advisor

Short Description

CN Bio develops human organ-on-chip technologies: devices that enable the formation of miniature models of human organs in the lab. CN Bio provides products and services to the pharmaceutical industry and in the past 3 years have used the CN Bio organ-on-chip models in drug discovery and drug safety programs with more than 25 pharmaceutical companies. CN Bio has also pursued research to develop disease organ-on-chip models with successful programs resulting in novel models of nonalcoholic steatohepatitis and Hepatitis B virus infection. CN Bio was the first company to reach the milestone of a 7-organ platform in February 2016.

CN Bio location

CN Bio location

Products

CN Bio produces a micro fluidic chip that “replicates the structure and functions of human organs, and enables precise control over tissue microenvironment so that physiological processes and drug exposures can be replicated in vitro”.

aaa

Noticeable publications

-Bioreactor technologies to support liver function in vitro, Advanced Drug Delivery Reviews, 2014

-Perfused multiwell plate for 3D liver tissue engineering, Lab on Chip, 2010

-Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease, World Journal of Gastroenterology, 2017

-Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system, Br J Cancer, 2014

-Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System, J Pharmacol Ep Ther, 2017

This is a unique website which will require a more modern browser to work! Please upgrade today!

Social Media Auto Publish Powered By : XYZScripts.com